BIOLASE Adds Two New Independent Directors to Its Board
June 10 2013 - 9:00AM
Marketwired
BIOLASE, Inc. (NASDAQ: BIOL), the world's leading manufacturer and
distributor of dental lasers, announced today that, its board of
directors (the "Board") has increased its size from four to six
members and, effective June 7, 2013, appointed Frederic H. Moll,
M.D. and Erin S. Enright to the Board. Dr. Moll and Ms. Enright
were each determined to be independent under the Nasdaq Listing
Standards by the Company's Board and met the requirements for
committee assignments as set forth in the respective committee
charters.
Frederic Moll, M.D., is Chairman and Chief
Executive Officer of Auris Surgical Robotics, Inc., the fourth
surgical robotics company he has founded. In 1995, Dr. Moll
co-founded Intuitive Surgical, Inc. (NASDAQ: ISRG), the world
leader in surgical robotics. He served as Intuitive's CEO through
1996 and a Director through 2004. Many credit Dr. Moll with
creating the surgical robotics industry. Dr. Moll has been
appointed to serve as a member of the Compensation Committee of the
Board.
"I'm excited to be joining the BIOLASE® Board because the
tissue-cutting capabilities of the WaterLase® could make it a
game-changer in medical and surgical specialties far afield from
the dental industry in which it is currently known and valued,"
said Fred Moll.
Prior to Intuitive Surgical, Inc., Dr. Moll founded
Endotherapeutics, which was acquired by U.S. Surgical in 1992. He
co-founded Origin Medsystems, Inc., which was also acquired in 1992
by Eli Lilly and later became an operating company in Guidant
Corporation. Dr. Moll served as medical director of Guidant's
surgical device division from 1992 to 1995. Before co-founding
Origin Medsystems, Dr. Moll invented the safety trocar, which many
experts believe created modern general laparoscopic surgery. He
also co-founded the intravascular robotics company, Hansen Medical,
Inc. and is a Director of the leading hard-tissue orthopedics
robotics company, MAKO Surgical Corporation.
Erin Enright is a medical device
executive, banker and attorney now serving as the President of Lee
Medical in Plainsboro, New Jersey, a manufacturer of Lee-Lok® bone
marrow needles. She is also the managing director of Prettybrook
Partners, which she operates with her partner, Stuart Essig, former
CEO of Integra Lifesciences (NASDAQ: IART), a former board member
of Zimmer Holdings, Inc. (NYSE: ZMH), and a current board member of
St. Jude Medical, Inc. (NYSE: STJ). Ms. Enright is also a Founding
Member and Director of TigerLabs, a Princeton-based fund and
technology accelerator. Ms. Enright has been appointed to serve as
a member of the Audit Committee of the Board.
"I believe there is a significant need for the hard tissue
cutting capabilities of the WaterLase in orthopedics, an
application in which the Company recently received an important FDA
clearance," said Ms. Enright. She also noted that... "with the
variety of bone and cartilage cutting, shaving and drilling
procedures currently performed with a rotating drill bit, I believe
that there is a significant opportunity for BIOLASE's WaterLase
technology to become used regularly in the orthopedic operating
room."
"We are extremely pleased with the addition of Fred and Erin to
our Board of Directors," said Federico Pignatelli, Chairman and
Chief Executive Officer. "Their experience and vision will be an
invaluable asset to the Board as it strategically guides the
Company forward into the next level of execution in our core laser
dental leadership and to also project our unique laser technologies
into new medical markets and opportunities. This is an exciting
time for the employees and stakeholders of BIOLASE."
About BIOLASE, Inc. BIOLASE, Inc. is a biomedical company that
develops, manufactures, and markets innovative lasers in dentistry
and medicine and also markets and distributes high-end 2D and 3D
digital imaging equipment and CAD/CAM intraoral scanners; products
that are focused on technologies that advance the practice of
dentistry and medicine. The Company's proprietary laser products
incorporate over 350 patented and patent-pending technologies
designed to provide biologically clinically superior performance
with less pain and faster recovery times. Its imaginative products
provide cutting-edge technology at competitive prices to deliver
the best results for dentists and patients. BIOLASE's principal
products are revolutionary dental laser systems that perform a
broad range of dental procedures, including cosmetic and complex
surgical applications, and a full line of dental imaging equipment.
BIOLASE has sold more than 22,500 lasers. Other laser products
under development address ophthalmology and other medical and
consumer markets.
For updates and information on WaterLase and laser dentistry,
find BIOLASE online at www.biolase.com, Facebook at
www.facebook.com/biolaseinc, Twitter at www.twitter.com/biolaseinc,
Pinterest at www.pinterest.com/biolase, LinkedIn at
www.linkedin.com/company/biolase, Instagram at
www.instagram.com/biolaseinc and YouTube at
www.youtube.com/biolasevideos.
BIOLASE® and WaterLase® are registered trademarks of BIOLASE,
Inc.
For further information, please contact: Michael Porter Porter,
LeVay & Rose, Inc. 212-564-4700
Biolase (NASDAQ:BIOL)
Historical Stock Chart
From Apr 2024 to May 2024
Biolase (NASDAQ:BIOL)
Historical Stock Chart
From May 2023 to May 2024